Tıpta Yenilikçi Yaklaşımlar Dergisi
Abbreviation: JIAM | ISSN (Online): 2757-7589 | DOI: 10.29329/jiam

Derleme Makalesi    |    Açık Erişim
Tıpta Yenilikçi Yaklaşımlar Dergisi 2021, Cil. 2(2) 38-47

İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekroz (MRONJ)

Zeynep Büşra Düzenli, Hasan Onur Şimşek & Burcu Gürsoytrak

ss. 38 - 47   |  DOI: https://doi.org/10.29329/jiam.2021.411.2

Yayın tarihi: Aralık 31, 2021  |   Okunma Sayısı: 144  |  İndirilme Sayısı: 316


Özet

Bifosfonatlar kemik metastazı ile tümör ve hiperkalsemi vakalarında yaşam standartlarını geliştirmek açısından kullanılan ilaçlardır. Bu ilaçlar için en tehlikeli yan etki olarak da osteonekroza sebebiyet verme riskinden bahsedilebilir. Bifosfonata bağlı olarak oluşan bu osteonekroz, ilk olarak 2002 yılında Marx ve Stern tarafından bifosfonat kullanan hastaların bir kısmında ağız içinde ortaya çıkan, iyileşmeyen, üstü mukoza ile örtülü olmayan ekspoze osteonekrotik kemik alanlarının varlığını farketmeleri ile teşhis edilmiştir.Bifosfonatların kullanımına bağlı olarak çene kemiklerinde görülen bu osteonekroz ‘Bisphosphonate-Related Osteonecrosis of the Jaw’ kelimelerinin baş harflerinin birleştirilmesinden oluşan BRONJ terimi olarak literatüre geçmiştir. Ancak yıllar içinde bu konuda hasta üzerinde yapılan çalışma ve araştırmalar artmış olup bu çeşit bir osteonekroza sadece bifosfonat türevi ilaçların değil; RANKL inhibitörü olan denosumab gibi kemoterapötik ilaçlar ve türevlerinin de sebep olduğu ortaya konmuştur. 2014 yılında ‘’Amerikan Oral ve Maksillofasiyal Cerrahi Derneği’’ (‘‘American Association of Oral and Maxillofacial Surgeons (AAOMS)’’) terimsel olarak değişikliğe gidilmesi gerekliliği nedeniyle ilaca bağlı olarak çene kemiklerinde görülen osteonekroz manasına gelen ‘’Medication-Related Osteonecrosis of the Jaw(MRONJ)’’ olarak terimi güncellemiştir. Günümüzde MRONJ ile ilgili çalışmalar yoğun bir şekilde tüm dünyada devam etmektedir.

Anahtar Kelimeler: Bifosfonatlar, Maksilla, Mandibula


Bu makaleye nasıl atıf yapılır

APA 6th edition
Duzenli, Z.B., Simsek, H.O. & Gursoytrak, B. (2021). İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekroz (MRONJ) . Tıpta Yenilikçi Yaklaşımlar Dergisi, 2(2), 38-47. doi: 10.29329/jiam.2021.411.2

Harvard
Duzenli, Z., Simsek, H. and Gursoytrak, B. (2021). İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekroz (MRONJ) . Tıpta Yenilikçi Yaklaşımlar Dergisi, 2(2), pp. 38-47.

Chicago 16th edition
Duzenli, Zeynep Busra, Hasan Onur Simsek and Burcu Gursoytrak (2021). "İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekroz (MRONJ) ". Tıpta Yenilikçi Yaklaşımlar Dergisi 2 (2):38-47. doi:10.29329/jiam.2021.411.2.

Kaynakça
  1. Guo, Z., Cui, W., Que, L., Li, C., Tang, X., & Liu, J. (2020). Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. International journal of oral and maxillofacial surgery, 49(3), 298-309. [Google Scholar]
  2. Kanis, J. A., Gertz, B. J., Singer, F., & Ortolani, S. (1995). Rationale for the use of alendronate in osteoporosis. Osteoporosis international, 5(1), 1-13. [Google Scholar]
  3. Marx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery, 63(11), 1567-1575. [Google Scholar]
  4. Filleul, O., Crompot, E., & Saussez, S. (2010). Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. Journal of cancer research and clinical oncology, 136(8), 1117-1124. [Google Scholar]
  5. Ferlito, S., Liardo, C., & Puzzo, S. (2010). Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva stomatologica, 59(11-12), 593-601. [Google Scholar]
  6. Russell, R. G. G., Xia, Z., Dunford, J. E., Oppermann, U. D. O., Kwaasi, A., Hulley, P. A., ... & Ebetino, F. H. (2007). Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Annals of the New York Academy of Sciences, 1117(1), 209-257. [Google Scholar]
  7. Rosella, D., Papi, P., Giardino, R., Cicalini, E., Piccoli, L., & Pompa, G. (2016). Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. Journal of International Society of Preventive & Community Dentistry, 6(2), 97. [Google Scholar]
  8. Ruggiero S., Dodson TB., Assael LA., Landesberg R., Marx RE., Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Pa- per on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust. Endod. J. 35:119-130, 2009 [Google Scholar]
  9. Dixon, R. B. (1997). Bone turnover in elderly canine mandible and tibia. J Dent Res, 76, 336. [Google Scholar]
  10. Tanna, N., Steel, C., Stagnell, S., & Bailey, E. (2017). Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. British dental journal, 222(2), 121-125. [Google Scholar]
  11. Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., ... & International Task Force on Osteonecrosis of the Jaw. (2015). Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of Bone and Mineral Research, 30(1), 3-23. [Google Scholar]
  12. Chiandussi, S., Biasotto, M., Dore, F., Cavalli, F., Cova, M. A., & Di Lenarda, R. (2006). Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofacial Radiology, 35(4), 236-243. [Google Scholar]
  13. Stockmann, P., Hinkmann, F. M., Lell, M. M., Fenner, M., Vairaktaris, E., Neukam, F. W., & Nkenke, E. (2010). Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations, 14(3), 311-317. [Google Scholar]
  14. Li, G. (2013). Patient radiation dose and protection from cone-beam computed tomography. Imaging science in dentistry, 43(2), 63-69. [Google Scholar]
  15. Stockmann, P., Hinkmann, F. M., Lell, M. M., Fenner, M., Vairaktaris, E., Neukam, F. W., & Nkenke, E. (2010). Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations, 14(3), 311-317. [Google Scholar]
  16. Crépin, S., Laroche, M. L., Sarry, B., & Merle, L. (2010). Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. European journal of clinical pharmacology, 66(6), 547-554. [Google Scholar]
  17. O'Ryan, F. S., Khoury, S., Liao, W., Han, M. M., Hui, R. L., Baer, D., ... & Lo, J. C. (2009). Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. Journal of Oral and Maxillofacial Surgery, 67(7), 1363-1372. [Google Scholar]
  18. Mücke, T., & Mitchell, D. A. (2015). Local and Microvascular Free Flaps in Patients with Medication-Related Osteonecrosis of the Jaw. In Medication-Related Osteonecrosis of the Jaws (pp. 93-101). Springer, Berlin, Heidelberg. [Google Scholar]
  19. Carey, J. J., & Palomo, L. (2008). Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic journal of medicine, 75(12), 871-879. [Google Scholar]
  20. Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., ... & Cislaghi, E. (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology, 20(1), 137-145. [Google Scholar]
  21. Dimopoulos, M. A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., ... & Bamias, A. (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 20(1), 117-120. [Google Scholar]
  22. Bagan, J. V., Jimenez, Y., Murillo, J., Hernandez, S., Poveda, R., Sanchis, J. M., ... & Scully, C. (2005). Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral oncology, 42(3), 327-329. [Google Scholar]
  23. Jasper, V., Laurence, V., Maximiliaan, S., Ferri, J., Nicot, R., & Constantinus, P. (2020). Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review. J Craniomaxillofac Surg, 48(4), 435-443. [Google Scholar]
  24. Ristow, O., & Pautke, C. (2014). Auto-fluorescence of the bone and its use for delineation of bone necrosis. International journal of oral and maxillofacial surgery, 43(11), 1391-1393. [Google Scholar]
  25. Fleisher, K. E., Doty, S., Kottal, S., Phelan, J., Norman, R. G., & Glickman, R. S. (2008). Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note. Journal of oral and maxillofacial surgery, 66(12), 2646-2653. [Google Scholar]
  26. Pautke, C., Bauer, F., Otto, S., Tischer, T., Steiner, T., Weitz, J., ... & Kolk, A. (2011). Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. Journal of Oral and Maxillofacial Surgery, 69(1), 84-91. [Google Scholar]
  27. Ristow, O., Otto, S., Troeltzsch, M., Hohlweg-Majert, B., & Pautke, C. (2015). Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). Journal of Cranio-Maxillofacial Surgery, 43(2), 290-293. [Google Scholar]
  28. Otto, S., Schreyer, C., Hafner, S., Mast, G., Ehrenfeld, M., Stürzenbaum, S., & Pautke, C. (2012). Bisphosphonate-related osteonecrosis of the jaws–characteristics, risk factors, clinical features, localization and impact on oncological treatment. Journal of Cranio-Maxillofacial Surgery, 40(4), 303-309. [Google Scholar]
  29. Kim, J. W., Kim, S. J., & Kim, M. R. (2014). Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. British journal of oral and maxillofacial surgery, 52(9), 854-859. [Google Scholar]
  30. Cano-Durán, J. A., Peña-Cardelles, J. F., Ortega-Concepción, D., Paredes-Rodríguez, V. M., García-Riart, M., & López-Quiles, J. (2017). The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). Journal of clinical and experimental dentistry, 9(8), e1051. [Google Scholar]
  31. Sarkarat, F., Motamedi, M. H. K., Jahanbani, J., Sepehri, D., Kahali, R., & Nematollahi, Z. (2014). Platelet-rich plasma in treatment of zoledronic acid-induced bisphosphonate-related osteonecrosis of the jaws. Trauma monthly, 19(2). [Google Scholar]
  32. Cicciù, M., Herford, A. S., Juodžbalys, G., & Stoffella, E. (2012). Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. Journal of Craniofacial Surgery, 23(3), 784-788. [Google Scholar]
  33. Ogata, K., Katagiri, W., Osugi, M., Kawai, T., Sugimura, Y., Hibi, H., ... & Ueda, M. (2015). Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model. Bone, 74, 95-105. [Google Scholar]
  34. Kim, J. W., Kim, S. J., & Kim, M. R. (2016). Simultaneous application of bone morphogenetic protein-2 and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of jaw. Journal of Oral Implantology, 42(2), 205-208. [Google Scholar]
  35. Cella, L., Oppici, A., Arbasi, M., Moretto, M., Piepoli, M., Vallisa, D., ... & Cavanna, L. (2011). Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. Head & face medicine, 7(1), 1-6. [Google Scholar]
  36. Kikuiri, T., Kim, I., Yamaza, T., Akiyama, K., Zhang, Q., Li, Y., ... & Shi, S. (2010). Cell‐based immunotherapy with mesenchymal stem cells cures bisphosphonate‐related osteonecrosis of the jaw–like disease in mice. Journal of Bone and Mineral Research, 25(7), 1668-1679. [Google Scholar]
  37. Rupel, K., Ottaviani, G., Gobbo, M., Contardo, L., Tirelli, G., Vescovi, P., ... & Biasotto, M. (2014). A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral oncology, 50(11), 1049-1057. [Google Scholar]